Multiple Sclerosis

Ocrelizumab Reduces Upper Extremity Disability Progression Risk in PPMS

Ocrelizumab Reduces Upper Extremity Disability Progression Risk in PPMS

By

Investigators observed that monoclonal antibody ocrelizumab may reduce the risk for upper extremity disability progression in patients with primary progressive multiple sclerosis.

Rituximab Beneficial in Secondary Progressive MS

Rituximab Beneficial in Secondary Progressive MS

For patients with secondary progressive multiple sclerosis (SPMS), treatment with rituximab is associated with a significantly lower Expanded Disability Status Scale (EDSS) score and delayed progression.

Bafiertam Gets Tentative Approval for Relapsing Multiple Sclerosis

Bafiertam Gets Tentative Approval for Relapsing Multiple Sclerosis

By

Bafiertam is a new fumarate bioequialent alternative to its prodrug, Tecfidera (dimethyl fumarate; Biogen).

Relapsing MS: Greater Treatment Satisfaction Following Switch to Teriflunomide

Relapsing MS: Greater Treatment Satisfaction Following Switch to Teriflunomide

By

Investigators reviewed patient-reported outcomes to assess treatment satisfaction with teriflunomide and also looked at feedback from physicians regarding the effectiveness of teriflunomide when used in routine clinical practice.

Infratentorial Lesions Beneficial for Differentiating  Fabry Disease vs MS

Infratentorial Lesions Beneficial for Differentiating Fabry Disease vs MS

By

Investigators sought to determine whether absence of lesions in 2 specific brain regions can distinguish Fabry disease from multiple sclerosis.

Alemtuzumab Linked to Clinical and MRI Disease Remission in Multiple Sclerosis

Alemtuzumab Linked to Clinical and MRI Disease Remission in Multiple Sclerosis

By

Researchers evaluated clinical and magnetic resonance imaging data from patients with relapsing-remitting multiple sclerosis treated with alemtuzumab.

Pregnancy Rates Among Patients With MS Rise Despite More Peripartum Issues

Pregnancy Rates Among Patients With MS Rise Despite More Peripartum Issues

By

Investigators retrospectively reviewed data to compare pregnancy prevalence and complications in women with and without multiple sclerosis.

Anti-MOG Antibody Test Identifies Atypical Features, Prognosis in MS

Anti-MOG Antibody Test Identifies Atypical Features, Prognosis in MS

By

Investigators assessed presenting symptoms in patients who tested positive for anti-myelin oligodendrocyte glycoprotein.

Interferon-Beta, Glatiramer Acetate Equally Effective for Relapsing-Remitting MS

Interferon-Beta, Glatiramer Acetate Equally Effective for Relapsing-Remitting MS

By

Investigators conducted a meta-analyses to determine whether injectable IFN-β and glatiramer acetate both decrease the annualized relapse rate and slow disease progression in patients with RRMS.

Palliative Care in MS Inpatients Rises From 2005 to 2014

Palliative Care in MS Inpatients Rises From 2005 to 2014

From 2005 to 2014, trends in palliative care use increased substantially among multiple sclerosis inpatients.

Prevalence of Pediatric Multiple Sclerosis Exceptionally High in Ontario, Canada Compared With Global Numbers

Prevalence of Pediatric Multiple Sclerosis Exceptionally High in Ontario, Canada Compared With Global Numbers

By

Researchers provide a practical, valid method to estimate the incidence and prevalence of MS in the pediatric population.

Certain Sites of Brain Lesions in MS Tied to Bowel Incontinence

Certain Sites of Brain Lesions in MS Tied to Bowel Incontinence

Specific locations of cerebral multiple sclerosis lesions appear to be associated with bowel incontinence.

NDA for Novel Relapsing Multiple Sclerosis Oral Treatment Submitted

NDA for Novel Relapsing Multiple Sclerosis Oral Treatment Submitted

By

Alkermes has submitted a New Drug Application to the FDA for a novel oral fumarate in development to treat relapsing forms of multiple sclerosis.

Family Planning in MS: Dispelling Myths and Encouraging Conversations

Family Planning in MS: Dispelling Myths and Encouraging Conversations

By

Rosalind C. Kalb, PhD, a clinical psychologist, offers her insights on how clinicians can address patient concerns about reproductive issues and MS.

Side Effects, Tolerability of Newer DMTs Similar in Pediatric, Adult Multiple Sclerosis

Side Effects, Tolerability of Newer DMTs Similar in Pediatric, Adult Multiple Sclerosis

By

Children with MS were more likely to receive a newer DMT prior to turning 18 years old compared with patients with CIS.

FDA Warns of Rare Stroke Risk With Multiple Sclerosis Drug

FDA Warns of Rare Stroke Risk With Multiple Sclerosis Drug

A new warning has been added to the multiple sclerosis drug Lemtrada (alemtuzumab) after rare reports of patients suffering strokes and tears in the lining of the arteries in the head and neck.

MS Relapse Drops During Pregnancy but Rises After

MS Relapse Drops During Pregnancy but Rises After

Rates of multiple sclerosis relapse decrease during pregnancy but increase postpartum.

Many Patients Do Not Engage Health Care Provider During MS Relapse

Many Patients Do Not Engage Health Care Provider During MS Relapse

The rate and frequency of relapse vary for patients with multiple sclerosis, and many report not visiting a health care provider during relapse.

FDA: Risk of Severe Increase in Disability Following MS Treatment Discontinuation

FDA: Risk of Severe Increase in Disability Following MS Treatment Discontinuation

By

From September 2010 to February 2018, the FDA has identified 35 cases of severe increased disability accompanied by the presence of new lesions on MRI that occurred 2 to 24 weeks after stopping treatment with fingolimod.

Ocrevus Labeling Updated With New Info on Timing of Vaccine Administration

Ocrevus Labeling Updated With New Info on Timing of Vaccine Administration

By

According to a Phase 3b open-label study, Ocrevus may interfere with the effectiveness of non-live vaccines.

Approaches for Better Diagnosis of Pediatric Multiple Sclerosis

Approaches for Better Diagnosis of Pediatric Multiple Sclerosis

By

Pediatric MS is predominantly inflammatory in nature, with a presentation that is similar to a number of other conditions.

Comorbidities in Multiple Sclerosis: Effects on DMTs, the Treatment Team, and More

Comorbidities in Multiple Sclerosis: Effects on DMTs, the Treatment Team, and More

By

Having a higher burden of comorbidities is associated with greater disability progression and lower QoL, as well as increased healthcare utilization and mortality.

Rates of Multiple Sclerosis Relapses Vary Before, During, and After Pregnancy

Rates of Multiple Sclerosis Relapses Vary Before, During, and After Pregnancy

By

Investigators sought to determine relapse rates of multiple sclerosis decrease prior to pregnancy, during pregnancy, and postpartum.

A New Look at Demyelination and White Matter Density in Multiple Sclerosis

A New Look at Demyelination and White Matter Density in Multiple Sclerosis

By

Investigators propose that myelocortical multiple sclerosis may be a subtype of multiple sclerosis.

Cannabinoids Mildly Effective for Treating MS Symptoms in Adults

Cannabinoids Mildly Effective for Treating MS Symptoms in Adults

Cannabinoids may be mildly effective at treating spasticity, pain, and bladder dysfunction in adults with multiple sclerosis.

Physical Activity Decreases Vascular Comorbidities in Multiple Sclerosis

Physical Activity Decreases Vascular Comorbidities in Multiple Sclerosis

By

Investigators examine the role of physical activity and exercise in the modification of vascular comorbidities and risk factors in individuals with multiple sclerosis.

DMTs Do Not Moderate Disability in Patients With MS and Diabetes, Other Comorbidities

DMTs Do Not Moderate Disability in Patients With MS and Diabetes, Other Comorbidities

By

All participants were smokers or had either diabetes, cancer, depression, cardiovascular, respiratory, thyroid, or gastrointestinal disease and were receiving a DMT.

Glatiramer Acetate Associated With Long-Term Disability Improvements in MS

Glatiramer Acetate Associated With Long-Term Disability Improvements in MS

By

Natural history data from a subset of patients from the British Columbia MS database between 1980 to 1996 were used to create a continuous Markov model to model the projected course of disease in untreated people with RMS.

Fingolimod Compared With Glatiramer Acetate in Head-to-Head MS Study

Fingolimod Compared With Glatiramer Acetate in Head-to-Head MS Study

By

Compared with Copaxone injection, treatment with oral Gilenya significantly reduced the annualized relapse rate in patients with relapsing remitting multiple sclerosis.

Biobank Data Suggest Vitamin D Reduces Risk for Multiple Sclerosis

Biobank Data Suggest Vitamin D Reduces Risk for Multiple Sclerosis

By

Researchers categorized samples into quintiles based on 25(OH)D3 concentrations in healthy controls.

Sign Up for Free e-newsletters



CME Focus